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Abstract
Background: FoxC2 is an epithelial–mesenchymal transition (EMT) regulator which induces metastasis. The purpose
of this study is to assess the prognostic value of FoxC2 expression in non-small cell lung cancer (NSCLC), alone or
in combination with E-cadherin expression.
Methods: A retrospective study was conducted using immunohistochemistry to investigate FoxC2 and E-cadherin
expression in a cohort of 309 patients with surgically resected NSCLCs. The prognostic value of FoxC2 and E-cadherin
on overall survival (OS) and recurrence-free survival (RFS) was determined by Kaplan-Meier analysis and Cox
proportional hazard models.
Results: High FoxC2 expression was detected in 26.5 % of tumors, and significantly correlated with tobacco use
(p = 0.047), adenocarcinoma (p = 0.008) and nodal involvement (p < 0.001). Univariate analysis revealed its association
with OS (p = 0.036) and RFS (p = 0.011). By multivariate analysis, high FoxC2 expression lost its significance as an
independent predictor of recurrence (p = 0.077), while TNM stage, nodal status and the presence of high FoxC2 and
impaired E-cadherin expression retained independent prognostic significance in relation to both OS and RFS. Subset
analyses indicated that high FoxC2 expression was significantly associated with disease outcome in node-positive, but
not in node-negative patients.
Conclusion: Evaluation of FoxC2 expression, alone or in combination with E-cadherin expression, may help to stratify
NSCLC patients for risk of disease progression, pointing to this EMT regulator as a potential prognostic marker.
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Background
Non-small cell lung cancer (NSCLC) is the leading cause
of cancer-related mortality worldwide. Despite recent
therapeutic advances, the 5-year survival rate across all
stages of this malignancy is approximately 15 %, as the
majority of patients present at the diagnosis with ad-
vanced disease [1]. Although it is surgically curable when
diagnosed at early stage, metastasis remains the major
obstacle to long-term survival after surgical resection [2].
However, conventional staging parameters, such as the
tumor/node/metastasis (TNM) system, fail to provide
precise risk stratification that can identify patients more
likely to recur and have poor prognoses. Thus, there is an
urgent need for the identification of new and more reliable
prognostic markers and novel therapeutic targets.
Given the significant impact of metastasis on survival,
metastasis-related molecules may have this potential.
Epithelial-to-mesenchymal transition (EMT) is a
process by which cells undergo a developmental switch
from an epithelial to a motile mesenchymal phenotype
[3]. Essential for the development of embryonic meso-
derm, EMT is also considered to be one of the crucial
molecular mechanisms inducing tumor invasion and
metastasis [4, 5]. Loss of E-cadherin expression and the
subsequent reduction of the ability of cells to form stable
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cell-cell contacts is a hallmark of EMT [3]. Several tran-
scription factors, such as the basic helix-loop-helix pro-
tein Twist, the zinc-finger proteins Snail and Slug, the
E-box-binding protein ZEB1 and the forkhead box pro-
tein FoxC2 has been reported to induce EMT through
the repression of E-cadherin expression, thereby playing
pivotal roles in tumor metastasis [6–9].
FoxC2 is a member of the forkhead transcription fac-
tor family and an important regulator of lymphovascular
vessel formation in cardiovascular development and dis-
ease [10]. Recent studies suggest that FoxC2 is an EMT
inducer and correlates with tumor metastasis and angio-
genesis [9, 11, 12]. Furthermore, an in vitro study dem-
onstrated that FoxC2 lies at the crossroads of EMT and
cancer stem cell properties in breast cancer [13]. How-
ever, despite all these biochemical and functional find-
ings, the prognostic role of FoxC2 in cancers has not
been extensively studied, especially in the context of
lung cancer. Previously, we showed that a three-marker
model including FoxC2 accurately predicted survival of
stage I NSCLC by using immunohistochemistry in tissue
microarrays of 137 cases [14]. This result prompted us
to investigate FoxC2 expression and assess its prognostic
value in a larger clinical cohort of patients with NSCLC.
The aims of this study were: (1) to examine the ex-
pression of FoxC2 in surgically resected NSCLC and
correlate it with clinicopathologic characteristics com-
monly related to disease prognosis, in a cohort of 309
patients; (2) to analyze its prognostic significance in rela-
tion to clinical outcome, using subset analyses; (3) to de-
termine the prognostic impact of FoxC2 expression by
multivariate analysis, either as an independent parameter
or in combination with E-cadherin; (4) to identify sub-
sets of patients with undesirable outcomes after prog-
nostic stratification based on the expression levels of
these two markers. We suggest that FoxC2 may have a
role in promoting NSCLC invasiveness and is a promis-
ing independent predictor for recurrence and survival.
Methods
Patients and specimens
Archival formalin-fixed, paraffin-embedded specimens
from surgically resected NSCLC containing tumor and
adjacent normal tissues were collected from 309 patients
at Zhongshan Hospital between 2006 and 2010. In-
formed consent was obtained, and this study was ap-
proved by the ethics committee of Zhongshan Hospital.
All patients underwent lobectomy or pneumonectomy
with mediastinal lymph node dissection. Cases treated
preoperatively with chemo-and/or radiotherapy were ex-
cluded. Detailed information about patient demograph-
ics, clinical manifestation and histopathology was
collected retrospectively for all patients. Histologic clas-
sification of tumors was based on the World Health
Organization criteria. Tumor stage was determined ac-
cording to the TNM 7th edition of International Union
Against Cancer.
Follow-up and postoperative treatment
Criteria for adjuvant therapy included advanced disease
(chemotherapy) and better local disease control (radio-
therapy). The median follow-up period was 49 (range, 3
to 81) months, lasting through October 30, 2012. All pa-
tients were followed up quarterly in the first 2 years and
semi-annually thereafter. The treatment modality after
relapse varied among individuals, and 11 patients who
recurred received no treatment. The primary end point
was overall survival (OS) as measured from the date of
surgery to the date of death or last contact. Recurrence-
free survival (RFS) was calculated as the period from
surgery until the time of recurrence.
Tissue microarray and immunohistochemistry
All samples from patients with NSCLC were stained
with hematoxylin and eosin. Duplicates of 1 mm diam-
eter cores from the tumor center and noncancerous
margin (2 punches, designated as tumor and corre-
sponding normal tissue, respectively) were included in
each sample, along with controls, to ensure reproducibil-
ity and homogenous staining. Two tissue microarray
blocks were constructed, each containing 315 cores. Sec-
tions 4-μm thick were placed onto slides coated with 3-
aminopropyltriethoxysilane. The primary antibodies
were as follows: mouse monoclonal antibody against
FoxC2 (ab55004; Abcam, Cambridge, UK) diluted 1:100,
and mouse monoclonal antibody against E-cadherin
(ab1416; Abcam, Cambridge, UK) diluted 1:100. Immu-
nohistochemistry of paraffin sections was performed
using a two-step protocol (Novolink Polymer Detection
System; Novocastra, Newcastle, UK) according to the
manufacturer’s instructions. Briefly, paraffin sections
were deparaffinized and hydrated. After microwave anti-
gen retrieval, endogenous peroxidase activity was
blocked by incubation of slides in 0.3%H2O2, and non-
specific binding sites were blocked with Protein Block
(RE7102; Novocastra). After serial incubation with pri-
mary antibodies, Post Primary Block (RE7111; Novocas-
tra), and secondary antibody (Novolink Polymer RE7112;
Novocastra), the sections were developed in diaminoben-
zidine solution under a microscope and counterstained
with hematoxylin. Negative control slides that omitted the
primary antibodies were included in all assays.
Evaluation of immunohistochemistical staining
All samples were evaluated by two pathologists who
were blinded to the patients’ outcome. When a discrep-
ancy was found, consensus was reached using simultan-
eous examination by all two investigators. The level of
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immunoreactivity of FoxC2 was graded according to the
percentage of positively stained tumor cells (0, no stain-
ing; 1, 1–30 %; 2, 30–60 %; 3, >60 %). Only a grade of
greater than 3 was considered as a positive immunohis-
tochemistry result (high expression). The intensity of
staining was carefully determined and assessed using a
4-grade scale as well (0, no staining; 1, weak staining; 2,
moderate staining; 3, strong staining). A grade of greater
than 2 was considered as positive staining. Staining for
E-cadherin was graded by 3° compared to the staining
intensity of positive control core specimens: grade 0 (no
expression or minimal expression with less than 10 % of
tumor cells stained), grade 1 (reduced expression or het-
erogeneous expression), and grade 2 (preserved expres-
sion with more than 90 % of the tumor cells stained).
For the statistical analysis, expression was grouped into
two categories: 0 and 1, impaired expression; 2, pre-
served expression.
Statistical analysis
Associations between clinicopathologic characteristics
and protein expression intensities were evaluated with
the chi-square test. OS and RFS were calculated by the
Kaplan–Meier method and were analyzed by the log-
rank test. Univariate and multivariate analyses were
based on the Cox proportional hazards regression model
for independent prognostic value. SPSS 15.0 statistical
software (SPSS, Chicago, IL, USA) was used. A two-
tailed p-value of less than 0.05 was considered statisti-
cally significant.
Results
Pattern of FoxC2 expression in NSCLC and correlation to
clinicopathological parameters
Immunostaining of FoxC2 generally displayed a nucleo-
plasmic pattern, with a tendency for cytoplasmic
localization. In normal bronchial and alveolar epithelial
cells, FoxC2 staining was very weak and nearly negative in
some cases. On the other hand, increased FoxC2 staining
was observed in NSCLC tissues, with 82 (26.5 %) tumors
showing a high level of expression. Representative images
are shown in Fig. 1. None of cells morphologically exhib-
ited a spindle-cell transdifferentiation that is characteristic
of EMT.
Correlations of FoxC2 expression with clinicopatho-
logic parameters are shown in Table 1. FoxC2 expression
showed a significant correlation with tobacco use (p =
0.047) and pN status (p < 0.001). Notably, high FoxC2
expression correlated with the histologic type of adeno-
carcinoma (p = 0.008). No significant associations were
noted between FoxC2 expression and other clinicopath-
ologic variables.
High expression of FoxC2 as a prognostic factor in
patients with NSCLC
Five-year OS and RFS rates were 46.3 % and 38.1 % re-
spectively for the entire cohort. Patients with FoxC2
positive tumors had a significantly worse prognosis com-
pared to those with low FoxC2 expression (OS, 43.6 %
vs. 64.5 %, p = 0.0028; RFS, 33.4 % vs. 56.0 %, p = 0.0012;
Fig. 2a, b). The univariate analysis indicated that FoxC2
expression, as well as TNM stage and nodal involvement
had a marked influence on OS and RFS. In the multi-
variate analysis, FoxC2 lost its value as an independent
predictor of recurrence (p = 0.077), although it was iden-
tified as an independent prognostic factor for OS (p =
0.039). Nodal status and TNM stage, two established
prognostic predictors for NSCLC, remained correlated
with both OS and RFS.
We then investigated the association between FoxC2
expression and prognosis, using various subset analyses.
High expression of FoxC2 showed a significant correl-
ation with poorer outcome in patients with adenocarcin-
oma (p = 0.018; Fig. 2d), whereas no prognostic impact
was verified in those with squamous cell carcinoma. Pa-
tients with high FoxC2 expression had a worse prognosis
regardless of gender (male, p =0.011; female, p = 0.023;
Fig. 2e, f, respectively) or smoking status (smoker, p =
0.035; never smoker, p = 0.014; Fig. 2g, h, respectively).
The prognostic value of FoxC2 expression was also ex-
amined in patients with different pT and pN status.
FoxC2 was found to be prognostic in both pT1 and
pT2-4 subsets, whereas could not differentiate outcome
for patients without nodal involvement (pN0, p = 0.167;
Fig. 2k). Conversely, FoxC2 demonstrated remarkable
prognostic significance when combined with nodal in-
volvement. Node-positive tumors with high FoxC2 ex-
pression displayed a much poorer outcome compared to
node-positive tumors expressing low levels of the pro-
tein (pN1-2, p = 0.008; Fig. 2l). Thus, FoxC2 expression
identifies a subgroup of patients with nodal metastasis
highly prone to progression.
High FoxC2 expression was associated with impaired E-
cadhern expression and a combination of the two
markers’ staining results identified a subset of patients
with much worse prognosis in NSCLC
E-cadherin expression was primarily membranous in
normal and tumor cells. Impaired expression for E-
cadherin was observed in 41.1 % of 309 patients (Fig. 1).
Associations of E-cadherin expression with clinicopatho-
logic characteristics are shown in Table 1. E-caherin
expression exhibited no significant correlations with any
of the clinicopathologic variables, except nodal involve-
ment (p = 0.041). Patients with impaired E-cadherin ex-
pression had a shorter RFS compared to those with
preserved expression of E-cadherin (OS, 42.2 % vs.
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Fig. 1 Representitive examples of FoxC2 and E-cadherin expression in NSCLC and normal lung tissue. Immunoreactivity of FoxC2 was mainly
detected in the cytosol and nuclei, while E-cadherin expression was primarily membranous. High level of FoxC2 expression was correlated with
impaired E-cadherin expression. a and c preserved expression of E-cadherin in normal tissue; (b and d) weak expression of FoxC2 in normal tissue;
(e and g) preserved expression of E-cadherin in NSCLC; (f and h) low expression of FoxC2 in NSCLC; (i and k) impaired expression of E-cadherin
in NSCLC; (j and l) high expression of FoxC2 in NSCLC
Table 1 Correlations between staining of Foxc2, E-cadherin and clinicophathologic characteristics in 309 NSCLC patients
Variables Foxc2-L Foxc2-H p E-cadherin-I E-cadherin-P p
n = 227 n = 82 n = 127 n = 182
Age
≤ 65 89 26 0.062 45 70 0.551
> 65 138 56 82 112
Sex
Male 154 55 0.891 90 119 0.329
Female 73 27 37 63
Tobacco use
No 117 35 0.047 59 93 0.223
Yes 110 47 68 89
Pathological type
Adenocarcinoma 131 58 0.008b 77 112 0.653b
Squamous cell carcinoma 76 13 40 49
Othera 20 11 10 21
TNM stage
I 45 17 0.679 22 40 0.432
II–III 182 65 105 142
pT status
T1 57 18 0.549 33 42 0.516
T2-4 170 64 94 140
pN status
N0 79 12 < 0.001 30 61 0.041
N1-2 148 70 97 121
Pleural involvement
No 181 68 0.372 98 151 0.245
Yes 46 14 29 31
Differentiation
Well/moderate 85 33 0.606 45 73 0.338
Poor 142 49 82 109
Vascular invasion
No 200 71 0.617 109 162 0.568
Yes 27 11 18 20
FoxC2-H high expression of FoxC2; FoxC2-L low expression of FoxC2
E-cadherin-I impaired expression of E-cadherin; E-cadherin-P preserved expression of E-cadherin
a Other including adenosquamous carcinoma, mucoepidermoid carcinoma, carcinosarcoma, large-cell carcinoma, and atypical carcinoid
b p value was analyzed by Adenocarcinoma vs. non- Adenocarcinoma using the chi-square test
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58.6 %, p = 0.061; RFS, 34.9 % vs. 55.3 %, p = 0.031;
Fig. 3). The univariate analysis showed that E-cadherin
expression had a significant influence on OS and RFS.
However, E-cadherin lost its significance as an independ-
ent predictor of recurrence (p = 0.092) and survival (p =
0.098) in the multivariate analysis.
The association between FoxC2 and E-cadherin ex-
pression was also examined. A significant inverse correl-
ation was found in both adenocarcinoma and squamous
cell carcinoma (Table 2).
To investigate the accumulative effect of FoxC2 and E-
cadherin expression on the prognosis of NSCLC, pa-
tients were classified into 4 groups: Group 1, low FoxC2
and preserved E-cadherin (n = 69); Group 2, low FoxC2
and impaired E-cadherin (n = 158); Group 3, high Foxc2
and preserved E-Cadherin (n = 47); and Group 4, high
Foxc2 and impaired E-cadherin (n = 35). Significant dif-
ferences in disease outcome were found among the 4
groups with regards to OS or RFS (Fig. 4; Table 3).
Group 1 exhibited a more favorable clinical outcome
(OS and RFS, 75.5 % and 62.1 %, respectively) as com-
pared to Group 4 (OS and RFS, 20.7 % and 16.9 %, re-
spectively), while Group2 and 3 showed an intermediate
prognosis. Moreover, the multivariate analysis demon-
strated that the presence of high FoxC2 expression in
combination with impaired E-cadherin expression was
an independent prognostic factor for shortened OS (p
=0.002) and RFS (p =0.035) (Table 3).
Discussion
The heterogeneous clinical outcomes of patients with
NSCLC of the same stage lead the investigators to
search for additional predictive and prognostic markers
that might optimize risk-adjusted therapeutic strategies.
Recent studies suggested that the activation of an EMT
program in tumors may significantly contribute to dis-
ease progression. On this basis, we sought to investigate
the role of FoxC2, one EMT-related molecule, in NSCLC
invasiveness, as well as to evaluate its prognostic value.
Our results showed that high expression of FoxC2 sig-
nificantly correlated with early recurrence and shortened
survival (Fig. 2a and b). Subgroup analyses according to
Fig. 2 Kaplan-Meier survival analysis in patients with NSCLC. a and b
Kaplan-Meier analysis of overall and recurrence-free survival according
to FoxC2 expression level. c and d Subsets of patients with squamous
cell carcinoma and adenocarcinoma. e and f Subsets of male and
female patients. g and h Subsets of smokers and never smokers. i and
j Subsets of pT status. k and l Subsets of pN status. High FoxC2
expression was associated with both shortened survival and increased
recurrence in the entire cohort of patients. Subset analyses indicated
that patients with high FoxC2 expression had a worse prognosis
regardless of gender, smoking status and pT status. As for patients with
squmous cell carcinoma and those without nodal involvement, FoxC2
was not found to be prognostic
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gender, smoking status and pT status showed consistent
findings with regards to OS. In line with our results,
Nishida et al. [11] reported a similar prognostic role of
FoxC2 by investigating its mRNA expression in a series
of 70 esophageal carcinoma cases. Analogous observa-
tion has also been recently reported for gastric carcin-
oma in a retrospective study of 325 patients using
immunohistochemical analysis [15]. In the multivariate
analysis, FoxC2 status has a prognostic impact on OS,
but not RFS, independent of other prognostic factors
that include node status and TNM stage. More import-
antly, the combined evaluation of FoxC2 with E-
cadherin demonstrated independent prognostic signifi-
cance in relation to both survival and recurrence (Table 3
and Fig. 3). A combination of the two markers seems to
define a subgroup of patients with the worst clinical
outcome within the entire cohort. This finding high-
lights the potential of the combination of these two
molecules as a more accurate indicator in predicting
disease evolution.
E-cadherin is a major cell-to-cell adhesion molecule
that plays a critical role in the development and main-
tenance of cell polarity and tissue architecture [16]. Loss
of E-cadherin expression is considered to be a hallmark
of EMT and correlates with tumor invasiveness, metasta-
sis and prognosis [17, 18]. One finding of our study is
the starkly inverse association between FoxC2 and E-
cadherin expression in both lung adenocarcinoma and
squamous cell carcinoma. This seems to support the role
of FoxC2 as a strong repressor of E-cadherin in lung
cancer. The molecular mechanism behind this correl-
ation was disclosed by the experimental study of Morta-
zavi et al. [19] on NSCLC cell lines, which revealed that
FoxC2 can repress E-cadherin expression through down-
regulating p120ctn, a regulatory protein that stabilizes E-
cadherin at the adhesion junctions of epithelial cells
[20], by directly suppressing its promoter activity. How-
ever, an earlier study described FoxC2 as a much weaker
repressor of E-cadherin in breast cancer cells [9]. This
inconsistency may be attributed to the different tumor
types involved in the two studies. The fact that protein
expression of E-cadherin was investigated in our study
while mRNA expression was observed in theirs might
also contribute to this inconsistency. On the other hand,
as loss of E-cadherin expression is believed to be a hall-
mark of EMT, the inverse correlation between FoxC2
and E-cadherin expression implicates that FoxC2 may be
involved in the EMT process in lung malignancy. A sub-
set of tumors with high FoxC2 and impaired E-cadherin
status, exhibiting a stronger EMT profile, could possess
more metastatic potential and have a worse prognosis,
which was corroborated by our results.
We found that FoxC2 expression was heterogeneously
present in lung adenocarcinoma and squamous cell car-
cinoma. A high level of FoxC2 expression was more fre-
quently found in adenocarcinomas. The biological
reason for this phenomenon is unknown. Nevertheless,
it is comprehensible, considering the fact that gene
Table 2 Relationship between FoxC2 and E-cadherin expression according to pathological subtype
Squamous cell carcinoma (n = 97) Adenocarcinoma (n = 189)
FoxC2 expression FoxC2 expression
FoxC2-L (%) FoxC2-H (%) FoxC2-L (%) FoxC2-H (%)
E-cadherin expression E-cadherin-L 11 (42.3) 15 (57.7) 21 (35.0) 39 (65.0)
E-cadherin-H 65 (91.5) 6 (8.5) 110 (85.3) 19 (14.7)
P <0.0001 <0.0001
Fig. 3 Kaplan-Meier survival analysis of overall and recurrence-free survival according to E-cadherin expression level in patients with NSCLC.
a Overall survival; b Recurrence-free survival
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Fig. 4 Kaplan-Meier survival analysis in patients with NSCLC according to the combination of FoxC2 and E-cadherin expression. The patients were
divided into four groups: Group 1, low FoxC2 and preserved E-cadherin; Group 2, low FoxC2 and impaired E-cadherin; Group 3, high Foxc2 and
preserved E-Cadherin; and Group 4, high Foxc2 and impaired E-cadherin. Patients with high FoxC2 and impaired E-cadherin expression had a
much poorer prognosis compared with the other groups. a Group 2 and 3 were evaluated together. b Group 2 and 3 were evaluated separately
Table 3 Univariate and multivariate analysis of factors associated with OS and RFS of 309 NSCLCs
OS RFS
Univariate analysis Multivariate analysisa Univariate analysis Multivariate analysisa
Variables HR 95 % CI p HR 95 % CI p HR 95 % CI p HR 95 % CI p
Age 1.50 1.01–2.89 0.092 1.12 0.62–2.36 0.147
(≤65 vs. > 65)
Sex 1.09 0.61–1.79 0.671 0.86 0.43–1.58 0.704
(female vs. male)
Tobacco use 1.26 1.17–3.08 0.143 1.03 0.52–1.97 0.766
(no vs. yes)
TNM stage 3.25 1.66–5.91 0.0007 2.02 0.93–4.37 0.012 3.08 1.49–6.24 0.0009 2.27 1.09–5.45 0.010
(I vs. II–III)
pT status 1.65 0.88–2.89 0.070 1.22 0.57–2.39 0.198
(T1 vs. T2-4)
pN status 4.19 2.10–7.72 0.0005 2.34 1.02–5.99 0.005 3.55 1.71–7.23 0.0004 2.76 1.46–5.89 0.003
(N0 vs. N1-2)
Pleural involvement 0.77 0.31–1.52 0.830 0.67 0.39–1.43 0.902
(no vs. yes)
Differentiation (well/moderate vs. poor) 1.32 0.72–2.61 0.127 1.07 0.51–1.91 0.722
Foxc2 expression 1.98 0.75–3.92 0.036 1.90 0.76–4.05 0.039 2.13 1.08–4.15 0.011 1.54 0.89–3.67 0.077
(low vs. high)
E-cadherin expression 2.03 0.97–4.12 0.024 1.77 0.79–3.78 0.098 2.09 1.12–4.37 0.043 1.38 0.65–2.99 0.092
(preserved vs. impaired)
Foxc2/E-cadherin expression
1 vs. 2 1.45 0.63–2.80 0.117 1.35 0.76–2.55 0.122
1 vs. 3 1.70 0.88–3.23 0.062 1.47 0.71–2.68 0.103
1 vs. 4 3.04 1.23–5.75 0.0009 2.41 1.12–4.67 0.002 2.55 1.29–5.16 0.008 2.06 0.87–4.17 0.035
1 vs. 2 + 3 + 4 1.85 0.90–3.53 0.026 1.34 0.64–2.23 0.168 1.56 0.74–3.05 0.071
OS overall survival; RFS recurrence-free survival
aVariables were adopted for their prognostic significance by univariate analysis
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expression profiles differ substantially between the two
histological subtypes [21, 22]. Furthermore, it is interest-
ing to note that high FoxC2 expression was closely asso-
ciated with nodal involvement, as such a correlation was
also shown by Watanabe et al. [23] in a study of 77 pa-
tients with extrahepatic cholangiocarcinoma. Corres-
pondingly, the presence of FoxC2 showed a remarkable
prognostic impact when combined with nodal status.
Node-positive tumors with high FoxC2 expression ex-
hibited a poorer outcome compared to those expressing
low levels of the gene, whereas no such effect was found
in node-negative tumors (Fig. 2k and l). Thus, FoxC2
identified a group of patients with node involvement
highly inclined to disease progression. This may reflect a
stronger destructive role of the protein in NSCLC with
nodal metastasis, leading to a more malignant tumor
phenotype.
Conclusions
In conclusion, even though FoxC2 alone is an independ-
ent predictor for survival in NSCLC, combined evalu-
ation of FoxC2 and E-caherin expression defines a new
subgroup of patients with both shortened survival and
earlier recurrence. Moreover, the assessment of FoxC2
status in node-positive patients helps identify a subset of
tumors with a more aggressive phenotype. These could
be of potential clinical relevance by providing new cri-
teria for risk stratification and making these subgroups
accessible for more aggressive or alternative therapy.
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